"D-VRd increased the depth and durability of responses, significantly reduced the risk of disease progression or death, and nearly doubled the rate of sustained minimal residual disease ...

Biologic heterogeneity in myeloma supports subtype-specific approaches, and t(4;14) defines a clinically meaningful subset with distinct pathway activation and historically aggressive behavior.

Discover inspiring messages of hope from cancer survivors, emphasizing resilience, scientific advancements, and the importance of community support. Reflecting on many years with multiple myeloma, ...

Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth ...

Multiple myeloma (MM) is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Patients experience periods of relapse and remission, with prognosis ...